KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Cash from Financing Activities: 2012-2024

Historic Cash from Financing Activities for Travere Therapeutics (TVTX) over the last 13 years, with Dec 2024 value amounting to $139.4 million.

  • Travere Therapeutics' Cash from Financing Activities fell 142141.30% to -$65.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $79.0 million, marking a year-over-year increase of 11412.10%. This contributed to the annual value of $139.4 million for FY2024, which is 36.66% down from last year.
  • According to the latest figures from FY2024, Travere Therapeutics' Cash from Financing Activities is $139.4 million, which was down 36.66% from $220.1 million recorded in FY2023.
  • Travere Therapeutics' 5-year Cash from Financing Activities high stood at $237.8 million for FY2021, and its period low was $120.1 million during FY2022.
  • In the last 3 years, Travere Therapeutics' Cash from Financing Activities had a median value of $139.4 million in 2024 and averaged $159.9 million.
  • Per our database at Business Quant, Travere Therapeutics' Cash from Financing Activities skyrocketed by 6,248.92% in 2020 and then slumped by 49.51% in 2022.
  • Over the past 5 years, Travere Therapeutics' Cash from Financing Activities (Yearly) stood at $127.7 million in 2020, then spiked by 86.19% to $237.8 million in 2021, then plummeted by 49.51% to $120.1 million in 2022, then skyrocketed by 83.37% to $220.1 million in 2023, then slumped by 36.66% to $139.4 million in 2024.